-+ 0.00%
-+ 0.00%
-+ 0.00%

Avenus announced new oculomotor function and biomarker data for the phase 1 clinical trial of ARV-102, its Parkinson's disease treatment drug.

Zhitongcaijing·10/07/2026 11:09:14
Listen to the news
Avenus announced new oculomotor function and biomarker data for the phase 1 clinical trial of ARV-102, its Parkinson's disease treatment drug.